iparomlimab + tuvonralimab + regorafenib + chemotherapy

This combination therapy is an investigational regimen being evaluated for the first-line treatment of unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, specifically for patients with low PD-L1 expression (CPS < 1). The regimen consists of **QL1706**, a bifunctional antibody product developed by Qilu Pharmaceutical that co-formulates the anti-PD-1 monoclonal antibody **iparomlimab** and the anti-CTLA-4 monoclonal antibody **tuvonralimab**. This is combined with **regorafenib**, an oral multikinase inhibitor that targets pathways involved in angiogenesis (VEGFR1-3, TIE2), the tumor microenvironment (PDGFR-β, FGFR1), and oncogenesis (KIT, RET, and BRAF). The treatment also includes a chemotherapy backbone of either **XELOX** (capecitabine and oxaliplatin) or **SOX** (S-1 and oxaliplatin). By combining dual immune checkpoint blockade with anti-angiogenic targeted therapy and cytotoxic chemotherapy, the regimen aims to enhance anti-tumor activity in PD-L1-low populations where standard immunotherapy may be less effective.

Other names

QL1706 + regorafenib + XELOXQL1706 + regorafenib + SOXiparomlimab + tuvonralimab + regorafenib + capecitabine + oxaliplatiniparomlimab + tuvonralimab + regorafenib + S-1 + oxaliplatin